Terkko Navigator / Porkka, K(immo)*

Copy number alterations define outcome in Philadelphia chromosomepositive acute lymphoblastic leukemia

Incidence of myelodysplastic syndromes in Finland 1997-2016

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia

New insight to the role of microbes in the methane exchange in trees: evidence from metagenomic sequencing

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses

KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia

Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML

Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies

<em>ERCC6L2</em> defines a novel entity within inherited acute myeloid leukemia

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL

Dasatinib and navitoclax act synergistically to target NUP98-NSD1⁺/FLT3-ITD⁺ acute myeloid leukemia

Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

Germline alterations in a consecutive series of acute myeloid leukemia

Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia

Applications of genomic medicine in the treatment of diseases

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing

Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia

NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia